Center for Individualized Medicine, Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic College of Medicine, Rochester, Minnesota 55905, USA.
Genome Res. 2022 Jan;32(1):124-134. doi: 10.1101/gr.275889.121. Epub 2021 Dec 7.
Current understandings of individual disease etiology and therapeutics are limited despite great need. To fill the gap, we propose a novel computational pipeline that collects potent disease gene cooperative pathways to envision individualized disease etiology and therapies. Our algorithm constructs individualized disease modules de novo, which enables us to elucidate the importance of mutated genes in specific patients and to understand the synthetic penetrance of these genes across patients. We reveal that importance of the notorious cancer drivers and fluctuate widely across breast cancers and peak in tumors with distinct numbers of mutations and that rarely mutated genes such as and have high disease module importance in specific individuals. Furthermore, individualized module disruption enables us to devise customized singular and combinatorial target therapies that were highly varied across patients, showing the need for precision therapeutics pipelines. As the first analysis of de novo individualized disease modules, we illustrate the power of individualized disease modules for precision medicine by providing deep novel insights on the activity of diseased genes in individuals.
尽管存在巨大的需求,但目前对个体疾病病因和治疗的理解仍然有限。为了填补这一空白,我们提出了一种新的计算管道,该管道收集有效的疾病基因协同途径,以预测个体化疾病病因和治疗方法。我们的算法从头开始构建个体化疾病模块,这使我们能够阐明特定患者中突变基因的重要性,并了解这些基因在患者之间的综合外显率。我们揭示了臭名昭著的癌症驱动基因的重要性在乳腺癌中差异很大,并在突变数量不同的肿瘤中达到峰值,而像 和 这样很少突变的基因在特定个体中具有很高的疾病模块重要性。此外,个体化模块破坏使我们能够设计定制的单一和组合靶向治疗方法,这些方法在患者之间差异很大,表明需要精准治疗管道。作为对从头开始的个体化疾病模块的首次分析,我们通过提供个体中患病基因活性的深刻新颖见解,说明了个体化疾病模块在精准医学中的强大功能。